SA Health Cancer Drug Committee TOR
PDF 260 KB
SA Health Cancer Drug Committee Terms of Reference
The SA Health Cancer Drug Committee (SAHCDC) is responsible to the South Australian Medicines Advisory Committee (SAMAC) for overseeing the development, approval and review of cancer chemotherapy protocols within SA Health Hospitals.
The scope of the SAHCDC includes chemotherapy protocols used in malignant haematology (for example leukaemia and myeloma) and oncology (solid tumours).
The SAHCDC provides final review and endorsement of new and updated protocols and support tools following submission by cancer services. Protocols are reviewed and assessed for effectiveness and suitability for endorsement using the National Health and Medical Research Council (NHMRC) Evidence levels guide (PDF 548KB)
The SAHCDC also enables urgent review of ‘non-standard’ cancer chemotherapy protocols for individual patient treatment when an endorsed protocol is not available.
Membership includes doctors, pharmacists, nurses and consumer representatives.
Chair — Dr Ganessan Kichenadasse, Lead, Statewide Clinical Cancer Network, Consultant, Medical Oncology, Flinders Medical Centre, Clinical Pharmacologist, Lecturer, Flinders University,
Deputy Chair – Dr David Yeung
Clinical Cancer Network Chair - Dr Ganessan Kichenadasse, Medicines and Technology Policy & Programs (MTPP)
Consumer Representative - Ms Karen van Gorp
Central Adelaide Local Health Network
Southern Adelaide Local Health Network
Northern Adelaide Local Health Network
Women’s and Children’s Health Network